Jonathan Behr
Partner at SV Health Investors
Cambridge, Massachusetts
Overview
Work Experience
Board Observer
2024 - Current
Sudo Biosciences is a biopharma company that designs and develops medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain.
Raised $183,000,000.00 from Leaps by Bayer, Velosity Capital, Frazier Life Sciences, Dementia Discovery Fund, UPMC Enterprises, Monograph Capital, Surveyor Capital, Sanofi Ventures, TPG and Eventide.
Partner
2019
The Dementia Discovery Fund (DDF) is a venture capital fund, delivering both high-impact therapeutics for age related dementias and financial returns by investing in, creating, and supporting innovative companies. I am responsible for helping to build the Fund’s investment portfolio by leading investments in new and established companies, working closely with the Fund’s existing portfolio companies in advisor and director roles, and developing and driving DDF’s investment strategy in collaboration with the leadership team. The DDF is managed by SV Health Investors, a healthcare and life sciences venture capital and growth equity firm.
Partner
2019
SV Health Investors is a boston-based venture capital firm focused on investments in biotechnology and healthcare industry.
Board Observer
2024
Montara Therapeutics is a biotechnology company.
Raised $16,000,011.00 from Two Bear Capital, KdT Ventures, Dolby Family Ventures and Dementia Discovery Fund.
Member Board of Directors
2023
Violet Therapeutics is a pre-clinical stage company leveraging first-in-class platforms to identify, map, and mine the cellular connectome.
Raised $10,600,000.00 from Mass General Brigham Ventures, Ono Venture Investment, UTEC - The University of Tokyo Edge Capital Partners and Dementia Discovery Fund.
Member Board of Directors
2020
Board Observer
2022
Member Board of Directors
2020 - 2022
QurAlis is a biotechnology company that creates precision medicine solutions to cure ALS and FTD.
Raised $135,500,000.00 from Amgen Ventures, Droia Ventures, MP Healthcare Venture Management, ALS Investment Fund, Polaris Partners, Mission BioCapital, EQT Life Sciences, Mitsui Global Investment, Dolby Family Ventures and Dementia Discovery Fund.
Board Observer
2022
Board Observer
2022
Independent Director, Parkinson's Research Ventures Ltd.
2023
The Parkinson’s UK Virtual Biotech (VB) programme was established in 2016 as a patient-led programme to discover and develop new treatments for Parkinson’s. It represents a core element of the strategy of the Parkinson’s UK charity (the “Charity”) to accelerate breakthroughs in research. Parkinson's Research Ventures (PRV) is a wholly-owned subsidiary of the Charity and was established in 2018 as a vehicle through which many of the financing and IP transactions for the VB Programme would be pursued. I am a volunteer independent director on the board of PRV.